# AI assessment of the revision 3 blinded items (verbatim; NOT an adjudication)

> **Status: AI ASSESSMENT, NOT AN OFFICIAL ADJUDICATION.** The owner supplied this on 2026-10-21. It describes itself as an AI assessment, produced after exposure to the compromised V001 sheets, and it recommends that it not be copied into the official adjudication logs. Its connection ids are the last ten characters of the blind ids; all 36 match the V2 items exactly, in V2 order. The coordinator has not independently verified any external claim in it (for example the FDA posting date). A machine-readable mapping is in [`ai_assessment.jsonl`](ai_assessment.jsonl).

---

Packet P3 — All 17 decisions
The main subject here is the Integra LifeSciences medical-device recalls and whether they can be linked to a measurable company outcome.
Connection	My decision	Economic meaning	Main reason
793909d493	Trivial	No	Chevron cleanup and Integra disclosure have no demonstrated economic relationship.
e977207739	Trivial	No	Norwegian fish-treatment capacity doesn't establish Integra's legal identity.
e14ea60127	Unverified	Unclear	Segment revenue exists, but recalled-product revenue isn't established.
d4a210e351	Unverified	Unclear	Subsidiary names are similar; precise legal identity and period need confirmation.
84e34126a1	Unverified	Unclear	Prior quality warning doesn't prove the later recall arose from the same facility or defect.
6fcb2b50a4	Confirmed, narrowly	Yes	Q2 financial reporting doesn't separately attribute a charge to MicroMyst.
db8b15dde2	Trivial	No	Parent revenue plus a subsidiary listing doesn't measure product exposure.
6b5b79c2d6	Unverified	Unclear	Exact device identifier found, but DUNS-to-listed-subsidiary legal identity isn't closed.
dc62481aff	Confirmed, narrowly	Yes	Q2 disclosure test finds no Extended Tip recall-specific charge.
87143e90ad	Trivial	No	Integra device and SunMed recall are unrelated products.
ea7badfe21	Confirmed	Yes	FDA recall and GUDID have the same device identifier; packaging units are identifiable.
ef9beef356	Confirmed	Yes	Extended Tip and MicroMyst are documented as a related recall family.
7b96650ced	Trivial	No	Insurance-premium retention and Integra recall attribution share only a generic research problem.
dffcf49273	Confirmed, narrowly	Yes	Q3 filing also lacks a separately attributed applicator recall charge.
ab3ea60347	Trivial	No	Two Extended Tip product variants belong to the same recorded FDA event; little additional information.
c487a29a99	Trivial	No	Combined Q2/Q3 disclosure check largely duplicates separately logged checks.
b30a491381	Unverified	Unclear	SunMed borrower identity was never established from the original loan schedule.
The most interesting P3 discovery
The FDA recall and GUDID connection is substantial because it joins an actual recalled product to its specific device identifier and packaging definition. That helps prevent a five-device box being confused with five separately counted units. 

accessdata.fda.gov
+1



I also found a particularly important timing detail: FDA's original recall page says June 20, 2025 was the posting date for Z-1958-2025, while the pilot's openFDA packet used a July 2, 2025 report date. Those must not be treated as the same first-public date. 

accessdata.fda.gov



The quarterly disclosure checks are useful negative findings, but they establish only the absence of specifically itemised charges—not that the recalls generated no costs. The 2025 Q2 and Q3 filings contain separately identified Boston/Braintree charges. 

sec.gov
+1



Packet P4 — All 19 decisions
This packet concerns vehicle recalls, component suppliers and whether replacement demand could translate into measurable supplier revenue or costs.
Connection	My decision	Economic meaning	Main reason
73cda6d4f7	Unverified	Unclear	2026 recall expansion and Autoliv's overall sales don't establish recall-specific economics.
b0599d4fbf	Trivial	No	Airbag remedy activity and Norwegian fish-treatment capacity aren't economically connected.
44c50ee6ea	Trivial	No	Toys R Us creditor exposure doesn't establish FCA recall liability.
939e76e791	Confirmed	Yes	Magna is directly named as the equipment-recall manufacturer.
ac9a4b8b08	Confirmed	Yes	Later NHTSA document explicitly identifies supersession of the earlier recall.
e0917a47b3	Confirmed	Yes	Magna's equipment recall expressly references Chrysler's camera recall.
8e30e145a7	Trivial	No	Autoliv candidate and fish-treatment history share only general measurement requirements.
0f55586e44	Trivial	No	Chevron cleanup exposure has no documented connection to Autoliv airbags.
25785c7b12	Unverified	Yes	Quarterly remedy figure is potentially useful, but I couldn't independently retrieve its cited PDF; remedied doesn't necessarily mean parts installed.
d57044feb7	Trivial	No	Historical BASF substitute-supplier requirements don't establish an Autoliv relationship.
7f15c91948	Unverified	Unclear	Magna's Ford claims can't automatically be attributed to the particular FCA recall.
d847304f89	Unverified	Unclear	Autoliv ASP appears in both records, but exact legal and temporal identity needs verification.
01a434479d	Trivial	No	BASF historical finding provides a generic research warning, not a camera-supplier connection.
34b9b927a9	Trivial	No	FCA airbag recall and BASF substitution case share no demonstrated economic exposure.
3268b1a342	Unverified	Unclear	Magna Electronics' precise legal identity isn't resolved by corporate-name and address similarities.
5f5830a476	Trivial	No	Insurance premium retention is not Autoliv's retained recall economics.
f22ae9b504	Trivial	No	BASF sales-scale caution is methodologically useful but unrelated to Magna's specific cost exposure.
6f8ec8a40c	Confirmed	Yes	Magna expressly describes repair/replacement and recall administration as potential costs.
6fec14bb2b	Confirmed	Yes	The 2026 NHTSA recall explicitly references the earlier 25V573 campaign.
The most significant P4 finding
I think 6f8ec8a40c is one of the best connections in the whole pilot.
The original mechanism suggested that a replacement recall could generate extra revenue for the relevant component supplier.
But Magna's own original corporate disclosure describes why a supplier responsible for defective equipment may instead incur repair, replacement and administrative costs. 

sec.gov



That's a good example of finding evidence that challenges an initially attractive economic thesis.
It doesn't prove Magna incurred a particular amount on this Chrysler recall. It does show that the assumed direction of the economic effect cannot be taken for granted.
Similarly, the NHTSA equipment report directly connects Magna, the affected rearview cameras and the vehicle manufacturers, but it doesn't identify who gets paid for the redesigned replacement cameras. 

static.nhtsa.gov
+1



And the later 2026 recall explicitly links back to the 2025 curtain-airbag recall, giving us useful retrospective event history—but not evidence that was available to a researcher in September 2025. 

static.nhtsa.gov
+1



What this tells me about the Knowledge Graph
There are two very different behaviours showing up.
The promising behaviour: connecting specific original records, identifying product-level information, discovering related recall versions, and finding evidence that undermines an economic assumption.
The weak behaviour: connecting unrelated historical investigations because both involve a broad concept like capacity, allocation, supplier exposure or net economics.
That's a meaningful design lesson.
I would eventually separate graph connections into different types, such as direct entity/event relationships, decisive measurement relationships, reusable methodological warnings and redundant observations. A methodological warning can still help an analyst, but it shouldn't be counted as a discovered economic connection.
I also wouldn't interpret my 10 supported recommendations as 10 independent discoveries. Some use the same filings, recall families or underlying disclosures.
My verdict
The system has demonstrated the ability to construct some genuinely useful, evidence-grounded research relationships. It has not yet demonstrated a valid investment edge or that the Knowledge Graph adds more value than structured search.
The biggest problems I see are:
- Too many generic historical analogies.
- Insufficient legal-entity and product-to-financial-statement joins.
- Retrospective evidence that could contaminate a historical hypothesis if timing controls fail.
- Repeated connections that can inflate research-output counts.
And because the original V001 sheets leaked arm identifiers, this analysis cannot become an independent blinded adjudication merely by copying my labels into the official logs.
My recommendation: preserve this report as an AI assessment, have an independent human check the proposed confirmations and contentious cases, then conduct the protocol's descriptive comparison. We shouldn't change the frozen rules to make the results look better.
What excites me is that the most valuable connections weren't stock recommendations. They were precise evidence checks that either strengthened or challenged a proposed economic mechanism.
